The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment

References

• Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243(5405), 290–293 (1973).
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, Abruzzo LV et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 110(8), 2991–2995 (2007).
   PubMed Web of Science ®Google Scholar
• Cortes JE, Talpaz M, Giles F et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 101(10), 3794–3800 (2003).
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113(8), 1619–1630 (2009).
   PubMed Web of Science ®Google Scholar
• Verma D, Kantarjian HM, Jones D et al. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood 114(11), 2232–2235 (2009).
   PubMed Web of Science ®Google Scholar
• Melo JV. BCR-ABL gene variants. Baillieres Clin. Haematol. 10(2), 203–222 (1997).
   PubMedGoogle Scholar
• Popovici C, Cailleres S, David M, Lafage-Pochitaloff M, Sainty D, Mozziconacci MJ. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib. Leuk. Lymphoma 46(9), 1375–1377 (2005).
   PubMed Web of Science ®Google Scholar
• Leibundgut EO, Jotterand M, Rigamonti V et al. A novel BCR-ABL transcript e2a2 in a chronic myelogenous leukaemia patient with a duplicated Ph-chromosome and monosomy 7. Br. J. Haematol. 106(4), 1041–1044 (1999).
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J. Natl Cancer Ins. 90(11), 850–858 (1998).
   PubMedGoogle Scholar
• Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 63(4), 789–799 (1984).
   PubMed Web of Science ®Google Scholar
• Hasford J, Baccarani M, Hoffmann V et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118(3), 686–692 (2011).
   PubMed Web of Science ®Google Scholar
• Mahon FX, Rea D, Guilhot J et al. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: update results of the STIM study. Blood (ASH Annual Meeting Abstracts) 118, 603a (2011).
   Web of Science ®Google Scholar
• Deininger M, O'brien SG, Guilhot F et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood (ASH Annual Meeting Abstracts) 114, 1126a (2009).
   Web of Science ®Google Scholar
• De Lavallade H, Apperley JF, Khorashad JS et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J. Clin. Oncol. 26(20), 3358–3363 (2008).
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Antolini L, Mahon FX et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J. Natl Cancer Ins. 103(7), 553–561 (2011).
   PubMedGoogle Scholar
• Kantarjian H, Talpaz M, O'brien S et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103(8), 2873–2878 (2004).
   PubMed Web of Science ®Google Scholar
• Hughes TP, Branford S, White DL et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 112(10), 3965–3973 (2008).
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Goldberg SL et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J. Clin. Oncol. 27(28), 4754–4759 (2009).
   PubMed Web of Science ®Google Scholar
• Cortes JE, Baccarani M, Guilhot F et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J. Clinl. Oncol. 28(3), 424–430 (2010).
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Lauseker M, Jung-Munkwitz S et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J. Clin. Oncol. 29(12), 1634–1642 (2011).
   PubMed Web of Science ®Google Scholar
• O'hare T, Walters DK, Stoffregen EP et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 65(11), 4500–4505 (2005).
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354(24), 2531–2541 (2006).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Levy V et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 115(18), 4136–4147 (2009).
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Deininger M et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22(6), 1200–1206 (2008).
   PubMed Web of Science ®Google Scholar
• Cortes JE, Jones D, O'brien S et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 28(3), 398–404 (2010).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 362(24), 2260–2270 (2010).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Shah NP, Cortes JE et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119(5), 1123–1129 (2012).
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Boqué C, Bradley Garelik M, Manos G, Steegmann JL. Molecular response kinetics and BCR-ABL reductions in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib vs imatinib: DASISION 3-year follow-up. Eur. Hematol. Assoc. Ann. Meeting 192 (2012).
   Google Scholar
• Radich JP, Kopecky KJ, Appelbaum FR et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 120(19), 3898–3905 (2012).
   PubMed Web of Science ®Google Scholar
• Giles FJ, Le Coutre PD, Pinilla-Ibarz J et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 27(1), 107–112 (2013).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354(24), 2542–2551 (2006).
   PubMed Web of Science ®Google Scholar
• Cortes JE, Jones D, O'brien S et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J. Clin. Oncol. 28(3), 392–397 (2010).
   PubMed Web of Science ®Google Scholar
• Rosti G, Palandri F, Castagnetti F et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 114(24), 4933–4938 (2009).
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 362(24), 2251–2259 (2010).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Hochhaus A, Saglio G et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 12(9), 841–851 (2011).
   PubMed Web of Science ®Google Scholar
• Larson RA, Hochhaus A, Hughes TP et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26(10), 2197–2203 (2012).
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Cortes JE, Kantarjian HM et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 119(15), 3403–3412 (2012).
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Brummendorf TH et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 118(17), 4567–4576 (2011).
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Kantarjian HM et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J. Clin. Oncol. 30(28), 3486–3492 (2012).
   PubMed Web of Science ®Google Scholar
• Preudhomme C, Guilhot J, Nicolini FE et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N. Engl. J. Med. 363(26), 2511–2521 (2010).
   PubMed Web of Science ®Google Scholar
• Simonsson B, Gedde-Dahl T, Markevarn B et al. Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 118(12), 3228–3235 (2011).
   PubMed Web of Science ®Google Scholar
• Cortes J, Quintas-Cardama A, Jones D et al. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer 117(3), 572–580 (2011).
   PubMed Web of Science ®Google Scholar
• Experts-in-Chronic-Myeloid-Leukemia. Price of drugs for chronic myeloid leukemia (CML), reflection of the unsustainable cancer drug prices: perspective of CML Experts. Blood 121, 4439–4442 (2013).
   PubMed Web of Science ®Google Scholar
• Yeung DT, Osborn MP, White DL et al. Early Switch to nilotinib does not overcome the adverse outcome for CML patients failing to achieve early molecular response on imatinib, despite excellent overall outcomes in the TIDEL II trial. Blood (ASH Annual Meeting Abstracts), 632a (2012).
   Google Scholar
• Darkow T, Henk HJ, Thomas SK et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. PharmacoEconomics 25(6), 481–496 (2007).
   PubMed Web of Science ®Google Scholar
• Noens L, Van Lierde MA, De Bock R et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113(22), 5401–5411 (2009).
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon FX et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J. Clin. Oncol. 28(14), 2381–2388 (2010).
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6), 872–884 (2013).
   PubMed Web of Science ®Google Scholar
• Chronic Myelogenous Leukemia. NCCN Clinical Practice Guidelines in Oncology Version 4(2013).
   Google Scholar
• Hughes TP, Hochhaus A, Branford S et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116(19), 3758–3765 (2010).
   PubMed Web of Science ®Google Scholar
• Wang L, Pearson K, Ferguson JE, Clark RE. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br. J. Haematol. 120(6), 990–999 (2003).
   PubMed Web of Science ®Google Scholar
• Hanfstein B, Muller MC, Hehlmann R et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26(9), 2096–2102 (2012).
   PubMed Web of Science ®Google Scholar
• Marin D, Hedgley C, Clark RE et al. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood 120(2), 291–294 (2012).
   PubMed Web of Science ®Google Scholar
• Neelakantan P, Gerrard G, Lucas C et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 121(14), 2739–2742 (2013).
   PubMed Web of Science ®Google Scholar
• Marin D, Ibrahim AR, Lucas C et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J. Clin. Oncol. 30(3), 232–238 (2012).
   PubMed Web of Science ®Google Scholar
• Saglio G, Kantarjian HM, Shah N et al. Early response (molecular and cytogenetic) and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): exploratory analysis of DASISION 3-year data. Blood (ASH Annual Meeting Abstracts) 120, 1675a (2012).
   Web of Science ®Google Scholar
• Hochhaus A, Hughes TP, Saglio G et al. Outcome of patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) based on early molecular response and factors associated with early response: 4-year follow-up data from enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). Blood (ASH Annual Meeting Abstracts) 120, 167a (2012).
   Web of Science ®Google Scholar
• Brümmendorf TH, Kantarjian HM, Gambacorti-Passerini C et al. Assessment of early molecular response as a predictor of long-term clinical outcomes in the phase 3 BELA study. Blood (ASH Annual Meeting Abstracts) 120, 69a (2012).
   Web of Science ®Google Scholar
• Jain P, Kantarjian H, Nazha A et al. Early responses predicts for better outcomes in patients with newly diagnosed CML: results with four TKI modalities. Blood 121(24), 4867–4874 (2013).
   PubMed Web of Science ®Google Scholar
• Nazha A, Kantarjian HM, Jain P et al. Disease patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) that have BCR-ABL transcript levels >10% At 3 month of therapy with Tyrosine Kinase Inhibitors (TKIs). Blood (ASH Annual Meeting Abstracts) 120, 3757a (2012).
   Web of Science ®Google Scholar
• Branford S, Fletcher L, Cross NC et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 112(8), 3330–3338 (2008).
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 16(2), 122–131 (2009).
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Corm S, Le QH et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 20(6), 1061–1066 (2006).
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Shah NP et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 367(22), 2075–2088 (2012).
   PubMed Web of Science ®Google Scholar
• Cortes J, Lipton JH, Rea D et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 120(13), 2573–2580 (2012).
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Seymour JF et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122(4), 515–522 (2013).
   PubMed Web of Science ®Google Scholar
• Takahashi N, Kyo T, Maeda Y et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 97(6), 903–906 (2012).
   PubMed Web of Science ®Google Scholar